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Dual orexin receptor antagonists (DORAs) are a potential treatment for insomnia that
function by blocking both the orexin 1 and orexin 2 receptors. The objective of the current
study was to further confirm the impact of therapeutic mechanisms targeting insomnia on
locomotor coordination and ethanol interaction using DORAs and gamma-aminobutyric
acid (GABA)-A receptor modulators of distinct chemical structure and pharmacological
properties in the context of sleep-promoting potential. The current study compared rat
motor co-ordination after administration of DORAs, DORA-12 and almorexant, and GABA-A
receptor modulators, zolpidem, eszopiclone, and diazepam, alone or each in combination
with ethanol. Motor performance was assessed by measuring time spent walking on a
rotarod apparatus. Zolpidem, eszopiclone and diazepam [0.3–30mg/kg administered orally
(PO)] impaired rotarod performance in a dose-dependent manner. Furthermore, all three
GABA-A receptor modulators potentiated ethanol- (0.25–1.5 g/kg) induced impairment
on the rotarod. By contrast, neither DORA-12 (10–100mg/kg, PO) nor almorexant
(30–300mg/kg, PO) impaired motor performance alone or in combination with ethanol.
In addition, distinct differences in sleep architecture were observed between ethanol,
GABA-A receptor modulators (zolpidem, eszopiclone, and diazepam) and DORA-12 in
electroencephalogram studies in rats. These findings provide further evidence that orexin
receptor antagonists have an improved motor side-effect profile compared with currently
available sleep-promoting agents based on preclinical data and strengthen the rationale for
further evaluation of these agents in clinical development.
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INTRODUCTION
Orexin neurons are a cluster of cells located in the periforni-
cal lateral hypothalamic area. The neuropeptides orexin A and
B bind to and activate the orexin 1 and 2 receptors (OX1R
and OX2R, respectively) with differential selectivity; orexin A
binds both receptors with similar affinity while orexin B exhibits
approximately 10-fold selectivity for OX2R (Sakurai et al., 1998).
Recent advances have been made in the development of phar-
macological agents that antagonize orexin receptors and interest
in their potential clinical application has increased (Scammell
and Winrow, 2011). The most salient role for orexin signaling
is its regulation of arousal and vigilance stage control, but it has
also been implicated in several other processes including feeding,
reward, stress, and mood (Gotter et al., 2012). The neuronal net-
works underlying these processes are becoming better understood
as orexin receptor antagonists with greater selectivity have been
developed (Ohno and Sakurai, 2008).
Orexin neurons are active during the waking phase in ani-
mals, but are largely quiescent during the sleep phase (Yoshida
et al., 2001; Kiyashchenko et al., 2002). Genetic loss of orexin sig-
naling in canines and rodents and orexin deficiency in humans
causes symptoms of narcolepsy (Chemelli et al., 1999; Lin et al.,
1999; Nishino et al., 2000), indicating the importance of orexin
neurons in regulating sleep-arousal mechanisms. For example,
damaging orexin neurons using the neurotoxin hypocretin-2-
saporin alters sleep behavior in rats (Gerashchenko et al., 2003)
and acute optogenetic silencing of these cells in vivo induces slow-
wave sleep in mice (Tsunematsu et al., 2011). Orexin neurons of
the lateral hypothalamus project to nuclei involved in regulating
arousal and vigilance state. OX1R and OX2R have overlapping
expression in these regions, with OX2R having selective expres-
sion in tuberomammillary nuclei of the hypothalamus, primarily
responsible for driving histamine-mediated arousal (Lin et al.,
1988; Trivedi et al., 1998; Marcus et al., 2001). Both receptors
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are expressed in brainstem nuclei involved in sleep regulation,
the exception being the selective expression of OX1R in the locus
coeruleus, most notably involved in the regulation of REM sleep
(Trivedi et al., 1998; Marcus et al., 2001). Regulation of orexin
neuron activity is provided both by excitatory projections from
the dorsomedial nucleus of the hypothalamus and by inhibitory
gamma-aminobutyric acid (GABA) inputs arising from the ven-
trolateral preoptic area (Thompson et al., 1996; Yoshida et al.,
2006). Increased inhibitory GABA activity on orexin neurons and
other sleep-related nuclei suppresses arousal and promotes sleep
(Saper et al., 2005).
Currently available sleep agents (including benzodiazepines
and related compounds) are typically GABA-A receptor modula-
tors, which are believed to mediate sedative effects through their
high affinity for the GABA-A α1 receptor subunit (Graham et al.,
1996; Rudolph et al., 1999; McKernan et al., 2000). Hypnotics
do not bind to the GABA-A receptor active site but instead
potentiate the affinity of GABA for the receptor via allosteric
modulation and result in increased inhibitor activity of the recep-
tor (Bianchi, 2010). GABA-A receptors are located throughout
the central nervous system (CNS), and have a role not only in
sleep induction, but in numerous other brain functions as well
(Sieghart and Sperk, 2002). This broad functionality can lead
to a variety of undesirable side effects such as unsteady gait,
next-day sedation, cognition deficits, lost balance and confu-
sion (Barker et al., 2004; Hindmarch et al., 2006; Otmani et al.,
2008; Vermeeren and Coenen, 2011). In an attempt to boost their
sleep-promoting effects, some chronic users of GABA-A recep-
tor modulators combine these agents with alcohol (Johnson et al.,
1998).
Ethanol acts, at least partially, by enhancing GABA transmis-
sion at GABA-A receptors (Hanchar et al., 2005; Lovinger and
Roberto, 2013) and chronic consumption of alcohol can result in
cross-tolerance to benzodiazepines (Devaud et al., 1996; Cagetti
et al., 2003). The actions of alcohol and benzodiazepines there-
fore converge mechanistically at GABA-A receptors, synergisti-
cally increasing their activity and potentially amplifying next-day
hangover effects. It is well-documented that co-administration
of alcohol and benzodiazepines/benzodiazepine receptor mod-
ulators can precipitate toxicities and accidents (Tanaka, 2002;
Kurzthaler et al., 2005), emphasizing the unmet need for novel
sleep-promoting agents with improved adverse-event profiles.
Recently, a number of orexin receptor antagonists includ-
ing SB-649868 (Bettica et al., 2012a), almorexant (Brisbare-Roch
et al., 2007), suvorexant (Winrow et al., 2011) and MK-6096
(Winrow et al., 2012) have demonstrated sleep-promoting prop-
erties in both animal and in clinical studies (Herring et al., 2012a;
Hoever et al., 2012; Bettica et al., 2012b). As these antagonists
target orexin receptors directly, we were interested in compar-
ing structurally distinct orexin receptor antagonists with a variety
of GABA-A receptor modulators, to evaluate their effects on
sleep architecture and potential for ethanol interactions. In foun-
dational studies, Steiner et al. (Steiner et al., 2011) compared
the effects of almorexant and zolpidem both alone and when
co-administered with ethanol in the context of rat locomotor per-
formance and myorelaxation in rotarod and grip strength assays.
Zolpidem affected both locomotor performance and grip strength
in a dose-dependent manner and was exacerbated by ethanol,
whereas neither of these changes were observed with almorexant
at dosages up to 300mg/kg (PO). The earlier study examined one
representative compound from each class, specifically in rotarod
and grip assays. In order to make a thorough assessment of the
mechanistic differences between the two drug classes, the current
study evaluated the locomotor performance and ethanol interac-
tion not only of almorexant, but also a chemically distinct dual
orexin receptor antagonists (DORA) of diverse structure, DORA-
12, as well as benzodiazepine and non-benzodiazepine GABA-A
modulators diazepam, eszopiclone and zolpidem. Further, loco-
motor performance was evaluated directly in the context of
sleep-promoting efficacy. These results demonstrate a distinct
difference between these sleep-promoting mechanisms, orexin
antagonism and GABA-A receptor activation, in terms of loco-
motor performance in the presence or absence of ethanol and in
the context of effects on sleep architecture.
MATERIALS AND METHODS
ANIMALS
All animal studies were performed in accordance with the
National Research Council Institute of Laboratory Animal
Resources Guide for the Care and Use of Laboratory Animals
and were approved by the Merck Institutional Animal Care and
Use Committee. Male Sprague-Dawley rats (180–225 g) were
maintained under normal laboratory conditions (controlled tem-
perature and food plus water ad libitum) under a regular 12-h
light/dark cycle (18:00 lights off and 06:00 lights on). Male
animals were used to avoid variability due to time-dependent
changes in estrus and rat sex-dependent differences in metabolic
enzyme activity. All behavioral tests were performed during the
light phase of the cycle, which in nocturnal rats is the normal rest-
ing phase. Animals were fasted overnight, housed two per cage
prior to testing and acclimated to the testing room for 30min
before testing. All studies used a between-subjects design.
COMPOUNDS AND FORMULATIONS
All pharmacological agents were synthesized by Merck chemists
or purchased from Sigma Company (Cream Ridge, NJ, USA) and
diluted in 20% Vitamin E-TPGS (d-alpha-tocopheryl polyethy-
lene glycol 1000 succinate) vehicle to a dose volume of 2mL/kg,
to be administered orally using standard stainless steel gavage
needles affixed to a 5 cc syringe (PO). Ethanol was diluted in
distilled water to a dose volume of 2mL/kg to be administered
intra-peritoneally (IP). After the acclimation period, rats were
administered compound or vehicle PO and tested after 30min
or were administered compound PO followed immediately by
ethanol IP and tested after 30min.
ROTAROD TEST
The rotarod apparatus (IITC Life Sciences, Woodland Hills, CA,
USA) consisted of a rod 60mm in diameter suspended 25.4 cm
from the floor of the apparatus. The speed of the rod could be
varied as desired. Rats were first trained over 2 days (2–3 trials) to
walk on the rod rotating at a constant speed (12 rpm). Rats were
then selected for inclusion in assays if they were able to remain
on the rod for 120 s as it was accelerated from 4 to 20 rpm (over
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150 s). Animals unable to perform the training task were excluded
from further testing. Roughly 10% of the animals failed to meet
this criterion.
During compound testing, rats were administered the test
compound and then returned to their home cage for the dura-
tion of the pretreatment period. The rats were then placed on the
rotarod at a speed that accelerated from 4 to 40 rpm over 300 s.
Latency to fall (time to the rat falling from the apparatus, up to
300 s) for each animal was digitally recorded by trip plates in the
platform which were triggered as soon as the rat fell from the rod.
One testing trial was performed for each animal.
PLASMA CONCENTRATIONS AND ETHANOL BLOOD LEVELS
At the end of the rotarod testing, which lasted approximately
35–40min, rats were immediately euthanized by carbon dioxide
overdose and blood samples were drawn via cardiac puncture
for compound level and/or blood alcohol content (BAC) test-
ing. Blood was centrifuged at 1300 RCF for 10min at 4◦C to
obtain serum for determination of compound plasma concentra-
tion and BAC. Ethanol analysis was performed using the Siemens
Ethanol_2 method on the Siemens Advia 1800 clinical chemistry
analyzer. The method utilizes alcohol dehydrogenase to catalyze
the oxidation of ethanol to acetaldehyde as well as reducing
nicotinamide adenine dinucleotide (NAD) to NADH. This causes
an increase in absorbance at 340 nm which is proportional to the
BAC (Clinical Pathology Diagnostic Group at Merck West Point).
Data were analyzed using a one-way analysis of variance fol-
lowed by a post-hoc Newmans-Keuls multiple comparison test;
p < 0.05 was considered significant. Data in the results tables
were normalized to controls.
RAT AMBULATORY POLYSOMNOGRAPHY
Male Sprague-Dawley rats (Charles Rivers Laboratory, Raleigh,
NC; n = 8–16/study, weight: 450–600 g) were singly housed
in polycarbonate cages (48.3 × 25.4 × 20.3 cm; LabProducts,
Seaford, DE) with free access to food and water in a 12:12
light:dark cycle. Prior to testing, adult rats of sufficient weight
were implanted with radio telemetric devices (TL10M3-F50-EEE,
Data Sciences International, Arden Hills, MN) and mean time
in vigilance states [active wake, light sleep, delta sleep, rapid eye
movement (REM) sleep] was determined as detailed previously
(Renger et al., 2004; Winrow et al., 2011, 2012). For these exper-
iments, vehicle and drug treatments were administered on three
consecutive days during the middle of the active or dark phase
(Zeitgeber Time 18:00–18:30) in a balanced cross-over design
such that each animal received both vehicle and drug in alternate
arms of the experiment. Mean within-subject change from vehicle
was determined for time spent in each vigilance state for the 2 h
following treatment. Population t-tests were used to determine
significance from vehicle under each condition.
RESULTS
INDIVIDUAL ACUTE EFFECTS ON MOTOR PERFORMANCE OF GABA-A
RECEPTOR MODULATORS, ETHANOL AND OREXIN RECEPTOR
ANTAGONISTS
The chemical structures of the orexin receptor antagonists
included in this study are shown in Figure 1.
FIGURE 1 | The chemical structures of almorexant and DORA-12. Both
almorexant and DORA-12 have similar antagonistic activity on both orexin
receptors with slight OX2R selectivity in affinity. Ki , competitive inhibition
binding constant determined in ligand displacement assays of Chinese
hamster ovary (CHO) cell membranes expressing recombinant human
OX1R and OX2R, Kb, functional inhibition of OX-A[Ala6,12]-induced calcium
mobilization in CHO cells expressing human OX1R and OX2R in fluorimetric
imaging plate reader (FLIPR) assays. The in vitro potency of DORAs,
including almorexant, for OX1R and OX2R is consistent across species and
less than 2-fold differences are observed between human and rat receptors
(Winrow et al., 2012).
Time spent walking on the rotarod by rats treated with
either GABA-A receptor modulators, orexin receptor antago-
nists, ethanol or vehicles was measured to assess the compounds’
individual effects on motor performance. Rotarod performance
30min after drug administration was impaired in a dose-
dependent manner by all the GABA-A receptor modulators tested
(Figure 2A). Zolpidem [F(4, 38) = 14.26, p < 0.01], eszopiclone
[F(4, 45) = 38.19, p < 0.01] and diazepam [F(4, 44) = 18.1, p <
0.01] all had a significant effect on rotarod performance. The
highest doses of zolpidem, eszopiclone and diazepam (10, 30, and
10mg/kg, respectively) reduced motor ability by 48.2, 56.1, and
57.8%, respectively, compared with vehicle treatment (p < 0.001;
Table 1). The lowest dose to result in significant impairment com-
pared with vehicle-treated animals was 3.0mg/kg for all of the
GABA-A receptor modulators [19.7, 15.1, and 30.2% impairment
for zolpidem, eszopiclone, and diazepam, respectively; p < 0.01
for all (Table 1)].
Ethanol administration dose-dependently impaired motor
performance in the rats [F(4, 30) = 11.83, p < 0.01] with doses of
0.5, 1.0 and 1.5 g/kg significantly decreasing latency to fall relative
to vehicle (Figure 2B). The highest ethanol dose (1.5 g/kg) pro-
duced a 64.6% decrease in motor ability in the rotarod compared
with vehicle-treated animals (p < 0.001, Table 1).
Almorexant doses ranging from 30 to 300mg/kg PO did not
affect the rats’ ability to walk on the rotarod [F(3, 36) = 0.23, p >
0.05] (Figure 2C and Table 1). Similarly, DORA-12 did not affect
rotarod performance over doses ranging from 10 to 100mg/kg,
PO [F(3, 38) = 0.54, p > 0.05] (Figure 2C and Table 1).
BAC and compound plasma concentrations weremonitored to
ensure that levels increased concomitantly with increasing doses
of ethanol or sleep-promoting compounds, respectively. Plasma
levels of the GABA-A receptor modulators increased with higher
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FIGURE 2 | Dose-response curve for latency to fall from rotarod for rats
administered (A) GABA-A receptor modulators, (B) ethanol, and (C)
orexin receptor antagonists. Comparison of GABA-A receptor
modulators, ethanol and orexin receptor antagonists in terms of latency to
fall using rotarod as a measure of motor performance. Paraoral acute
administration of zolpidem, eszopiclone, diazepam, and IP administration of
ethanol dose-dependently impairs rotarod performance. Paraoral doses of
orexin receptor antagonists, almorexant and DORA-12, do not impair
locomotor performance after acute administration. Data are shown as
mean ± standard error of the mean. ∗p < 0.05, ∗∗∗p < 0.001 for the level of
significance vs. the vehicle-treated group. ANOVA post-hoc Newman-Keuls
multiple comparison tests (n = 7–12). ANOVA, analysis of variance; PO, per
oral; V, vehicle.
doses (Table 1) and were accompanied by a greater reduction in
latency to fall. Similarly, BAC increased with increased doses of
ethanol (Table 1). In contrast, latency to fall was not reduced
by increasing doses of almorexant and DORA-12, despite con-
comitant increases in the plasma concentrations of these orexin
receptor antagonists (Table 1 and Figure 2).
Table 1 | Dose-response effects of ethanol, GABA-A receptor
modulators and orexin receptor antagonists on compound plasma or
blood alcohol concentrations and latency to fall from the rotarod.
Treatment Dosea [Compound]plasma/ Rotarod Latency to
BAC(µM) / (mg/dL)b performance fall (s)b
(% change)
ETHANOL TESTS
Vehicle V − 0 264.8 ± 15.5
Ethanol 0.25 <10 −17.2 219.1 ± 27.6
0.50 35.4 ± 4.8 −26.2* 195.4 ± 12.9*
1.0 107.0 ± 8.8 −28.2* 189.7 ± 9.9*
1.5 204.1 ± 11.3 −64.6*** 93.7 ± 10.6***
ZOLPIDEM TESTS
Vehicle V − 0 242.5 ± 12.3
Zolpidem 0.3 0.036 ± 0.004 −3.7 233.6 ± 10.4
1.0 0.115 ± 0.020 −16.9 201.4 ± 15.9
3.0 0.333 ± 0.040 −19.7* 194.6 ± 11.0*
10 0.878 ± 0.121 −48.2*** 125.6 ± 8.4***
ESZOPICLONE TESTS
Vehicle V − 0 267.9 ± 6.9
Eszopiclone 1.0 0.090 ± 0.01 −3.4 258.9 ± 12.1
3.0 0.400 ± 0.03 −15.1* 212.6 ± 8.2*
10 1.100 ± 0.12 −45.1*** 147.1 ± 13.0***
30 3.15 ± 0.53 −56.1*** 117.5 ± 7.0***
DIAZEPAM TESTS
Vehicle V − 0 231.8 ± 26.5
Diazepam 0.3 0.04 ± 0.01 −8.4 203.6 ± 10.4
1.0 0.05 ± 0.02 −15.7 182.3 ± 9.6
3.0 0.13 ± 0.08 −30.2*** 145.1 ± 13.9***
10 0.31 ± 0.15 −57.8*** 97.8 ± 7.9***
ALMOREXANT TESTS
Vehicle V − 0 235.4 ± 16.3
almorexant 30 0.62 ± 0.12 −2.6 229.3 ± 14.0
100 4.81 ± 0.37 −7.1 218.7 ± 14.0
300 11.81 ± 1.38 −3.2 227.9 ± 13.0
DORA-12 TESTS
Vehicle V − 0 229.0 ± 13.3
DORA-12 10 0.43 ± 0.04 +7.4 246.0 ± 9.8
30 0.97 ± 0.09 +6.4 243.6 ± 10.2
100 4.06 ± 0.40 +8.3 247.9 ± 13.8
ANOVA, analysis of variance; SEM, standard error of the mean; V, vehicle
Plasma/alcohol levels refer to time points between 35 and 40min after dosing
of compounds.
aDoses of zolpidem, eszopiclone and diazepam are given in mg/kg; doses of
ethanol are given as g/kg.
bMean ± SEM shown for compound concentrations in plasma, blood alcohol
concentrations (BAC) and Latency to fall.
*p < 0.05, ***p < 0.001 significance versus vehicle treatment group. ANOVA
post-hoc Newman-Keuls multiple comparison test.
DIFFERENTIAL SLEEP-PROMOTING EFFECTS OF ETHANOL, GABA-A
RECEPTOR MODULATORS AND DORA-12
To evaluate the effects of these compounds on locomotor activity
in the context of sleep promotion, the benzodiazepine (diazepam)
and non-benzodiazepine (eszopiclone and zolpidem) GABA-A
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receptor modulators, the orexin receptor antagonist DORA-12
and ethanol, were assessed for their ability to promote sleep in rats
at the highest doses tested in rotarod experiments. Almorexant
has been well-documented to promote sleep at dosages ranging
from 30 to 300mg/kg, the approximate maximum effect level
(Brisbare-Roch et al., 2007), and has been previously shown
in our lab to attenuate active wake at 100mg/kg for as long
as 7 h (Gotter et al., 2013). As seen in Figure 3, all treatments
with the exception of zolpidem 30mg/kg significantly attenu-
ated active wake during the 2 h following treatment (−6.0min ±
3.6min, p = 0.118, paired t-test for individual animals rela-
tive to vehicle). DORA-12 reduced the time spent in active
wake to a similar extent as eszopiclone (30mg/kg) and ethanol
(1.5 g/kg) (reductions of 13.5 ± 2.3, 14.0 ± 2.7, 12.7 ± 4.4min,
respectively), while diazepam 10mg/kg had the greatest effect
(20.4 ± 5.0min). Relative to vehicle, all treatments significantly
increased delta sleep time during the 2-h analysis period to similar
magnitudes, with increases ranging from 9.6 ± 4.6min in the
FIGURE 3 | Differential effects of ethanol, GABA-A receptor modulators
and DORA-12 on sleep stages. Mean time in active wake, delta, light and
REM sleep was monitored for 2 h after PO administration of ethanol (1.5
g/kg), eszopiclone (30mg/kg), zolpidem (10mg/kg), diazepam (10mg/kg), or
DORA-12 (30mg/kg). Three consecutive days of each treatment was
administered in a balanced cross-over design such that each subject
received drug and vehicle. Mean within-subject change relative to vehicle is
shown. Data were analyzed using within-subject paired t-tests relative to
vehicle (N = 8–16; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). PO, paraoral; REM,
rapid eye movement.
case of diazepam to 12.8 ± 2.9min for eszopiclone. DORA-12
increased delta sleep by 10.9 ± 1.4min. Light sleep, which is a
minor component of rat sleep, was only significantly affected by
diazepam in these studies. The most striking differences were on
REM sleep changes. Ethanol and diazepam had no effect on REM,
but eszopiclone and zolpidem both attenuated REM sleep relative
to vehicle (−4.2 ± 0.8 and −5.1 ± 0.9min, respectively), despite
the fact that zolpidem was not effective in significantly reducing
active wake in this experiment. DORA-12, on the other hand,
significantly increased REM sleep time relative to vehicle (by
6.6 ± 1.1min). We have recently shown that almorexant, dosed
at 100mg/kg during the active phase, has similar effects in terms
of the magnitude of active wake reduction as a 30mg/kg dose of
DORA-12 (Gotter et al., 2013), consistent with previous obser-
vations (Brisbare-Roch et al., 2007). These results demonstrate a
clear difference between the sleep promoted by the standard of
care for insomnia and the effects of DORA-12.
ACUTE EFFECT ON MOTOR PERFORMANCE OF GABA-A RECEPTOR
MODULATORS IN COMBINATIONWITH ETHANOL
Sub-threshold doses (below the doses observed to impair motor
performance) of the GABA-A receptor modulators zolpidem,
eszopiclone, and diazepam were identified from their respective
dose–response curves (Figure 2A). A minimum effective dose
of ethanol (1 g/kg) was identified that produced BAC ranging
from 106.9 ± 7.7mg/dL−139.1 ± 2.42mg/dL (Figure 2B). Sub-
threshold doses of the GABA-A receptor modulators were then
co-administered with the minimum effective dose of ethanol to
assess whether ethanol may have additive motor impairments
associated with GABA-A receptor modulators.
Diazepam 3.0mg/kg co-administered with ethanol reduced
rats’ latencies to fall from the rotarod by 63.4% compared with
vehicle (Figure 4A and Table 2). By way of comparison, rats
administered ethanol or diazepam alone demonstrated 30.8 and
15.5% decreases, respectively, in latency to fall (Table 2). In these
animals, there was a significant main effect of diazepam and
ethanol [F(1, 32) = 10.8 and 49.7, respectively, p < 0.001] as well
as a significant diazepam by ethanol interaction [F(1, 32) = 4.8,
p = 0.036]. Post-hoc analysis showed that animals administered
ethanol alone differed significantly from animals given only vehi-
cle (p < 0.05). Post-hoc tests also revealed that animals given
diazepam with ethanol differed from animals given diazepam or
ethanol alone (p < 0.05).
A similar pattern of effect was observed with eszopiclone. Both
eszopiclone and ethanol produced a main effect of treatment
[F(1, 34) = 7.78 and 12.58, p = 0.001 and 0.009, respectively];
however, there was no interaction when the two compounds
were given together, suggesting an additive effect. The percent
decrease in rotarod latency when eszopiclone was given without
and with alcohol was 12.1% and 34.5%, respectively. Post-hoc
analysis showed that animals administered ethanol (p > 0.05) did
not differ significantly from vehicle-vehicle group (Figure 4A and
Table 2).
Zolpidem also negatively impacted rotarod performance, as
indicated by a main effect of zolpidem treatment [F(1, 29) =
14.53, p < 0.001]. Ethanol likewise produced an effect in this
experiment, as indicated by a main effect [F(1, 29) = 25.49, p <
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FIGURE 4 | Interaction of ethanol with (A) GABA-A receptor
modulators or (B) orexin receptor antagonists on rotarod performance.
Effect of GABA-A receptor modulators and orexin receptor antagonists on
rotarod performance. Effects of zolpidem, eszopiclone, and diazepam were
tested using a minimum effective dose (MED) of ethanol and a MED of test
compound based on the results of the dose-response rotarod studies.
Effects of almorexant and DORA-12 were tested using doses well-above
those required to initiate sleep in combination with the MED of ethanol.
Data are shown as mean ± standard error of the mean. ∗p < 0.05 for the
level of significance vs. vehicle-vehicle group and #p < 0.05 denotes
significant difference from the vehicle-ethanol group. Two-Way ANOVA was
followed by post-hoc tests (Newman-Keuls multiple comparison tests,
n = 7–12). ANOVA, analysis of variance; D, diazepam; E, ethanol; Es,
eszopiclone; V, vehicle; Z, zolpidem.
0.001]. The interaction between ethanol and zolpidem was not
significant, indicating that the effects of these two compounds
on rotarod performance was additive [F(1, 29) = 1.53, p = 0.23].
The percent decrease in rotarod latency when zolpidem was
given without and with ethanol was 12.3 and 42.3%, respectively
(Figure 4A and Table 2).
ACUTE EFFECT ON MOTOR PERFORMANCE OF OREXIN RECEPTOR
ANTAGONISTS ADMINISTERED IN COMBINATION WITH ETHANOL
By contrast with the GABA-A receptor modulators, neither
almorexant nor DORA-12 potentiated motor performance
impairment when co-administered with ethanol (Figure 4B and
Table 2). In both the almorexant and DORA-12 experiments,
ethanol produced a main effect of treatment [F(1, 35 and 36) =
7.84 and 36.5, p = 0.008 and <0.001, respectively]. However,
neither almorexant nor DORA-12 produced a main effect of
treatment, and there was no interaction between either of the
two DORAs and ethanol. Rotarod performance was impaired
to a similar extent when given with and without almorex-
ant (22.5 and 22.3%, respectively). Likewise, rotarod perfor-
mance was impaired to a similar extent when ethanol was
given with and without DORA-12 (25.1 and 29.1%, respec-
tively). BACs were similar when ethanol was administered
alone or in combination with either one of the orexin recep-
tor antagonists (Table 2), demonstrating that neither DORA-
12 nor almorexant had a measureable impact on ethanol
metabolism.
DORA-12 and almorexant plasma concentrations were stable
when administered alone but fluctuated when co-administered
with ethanol. Co-administration of ethanol also resulted in fluc-
tuations in the drug–plasma concentrations of the GABA-A
receptor modulators (Table 2).
DISCUSSION
The aim of the current study was to evaluate the potential
impact of different insomnia therapeutic mechanisms on loco-
motor coordination in the presence or absence of ethanol relative
to doses effective in promoting sleep. The current work goes
beyond that of others (Steiner et al., 2011), by evaluating loco-
motor performance following treatment with multiple, distinct
compounds within each class—two orexin receptor antagonists,
a benzodiazepine and two non-benzodiazepine GABA-A recep-
tor modulators—in order to determine if these results were due
to pathway-dependent effects and not due to individual com-
pound idiosyncrasies. In addition, locomotor impairment was
evaluated in the context of sleep-promoting effects and sleep
architecture. These results demonstrate that, at equally effec-
tive sleep-promoting doses, GABA-A receptor modulators induce
substantial locomotor impairment and ethanol interaction rela-
tive to that observed in response to DORAs. This analysis also
illustrates fundamental differences in sleep architecture induced
by orexin receptor antagonists compared with GABA-A receptor
modulators.
The use of multiple, pharmacologically distinct compounds
from the orexin receptor antagonist and GABA-A receptor mod-
ulator classes indicates that the observed differences in locomotor
impairment are due to the different sleep-promoting mecha-
nisms. Studies in animals and humans have demonstrated consis-
tent sleep-promoting effects of orexin receptor antagonists with
distinct structural and pharmacological properties (Brisbare-
Roch et al., 2007; Winrow et al., 2011, 2012; Bettica et al.,
2012c; Herring et al., 2012b). Almorexant has been shown pre-
viously not to impair locomotor performance or to interact with
ethanol (Steiner et al., 2011). We have further demonstrated
that DORA-12 did not disrupt locomotor activity in the pres-
ence or absence of ethanol. DORA-12 is chemically distinct from
almorexant, has greater in vivo potency, a distinct pharmacoki-
netic profile and faster binding kinetics despite similar in vitro
activity at the receptor (Brisbare-Roch et al., 2007; Gotter et al.,
2013). These results indicate that antagonism of orexin signal-
ing promotes sleep, but does not significantly impair motor
function. Contrary to the effects seen with orexin receptor antag-
onists, three different GABA-A receptor modulators of distinct
chemical structure—a classic benzodiazepine, diazepam, and the
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Table 2 | Interaction of GABA-A receptor modulators and orexin receptor antagonists combined with a minimum effective dose of ethanol on
drug plasma concentration, blood alcohol concentrations and latency to fall from the rotarod.
Treatment Compound dose Ethanol dose [Compound]plasma BAC (mg/dL)a % Change in rotarod Latency to fall (s)a
(mg/kg) (g/kg) (µM)a performance
ZOLPIDEM TESTS
Vehicle V V – – 0 242.7 ± 10.0
Zolpidem 1.0 V 0.102 ± 0.02 – −12.3 212.9 ± 10.9
V 1.0 – 121.5 ± 14.2 −18.2* 198.6 ± 16.2*
1.0 1.0 0.086 ± 0.04 124.4 ± 11.7 −42.3* 140.1 ± 9.1*#
ESZOPICLONE TESTS
Vehicle V V – – 0 242.9 ± 12.4
Eszopiclone 3.0 V 0.42 ± 0.04 – −12.1 213.4 ± 15.6
V 1.0 – 106.9 ± 7.7 −16.3 203.4 ± 11.4
3.0 1.0 0.20 ± 0.07 114.8 ± 5.4 −34.5* 159.0 ± 12.1*#
DIAZEPAM TESTS
Vehicle V V – – 0 250.4 ± 13.8
Diazepam 3.0 V 0.103 ± 0.03 – −15.5 226.5 ± 15.8
V 1.0 – 139.1 ± 2.42 −30.8* 188.7 ± 12.5*
3.0 1.0 0.145 ± 0.04 119.8 ± 12.6 −63.4*# 94.6 ± 15.7*#
ALMOREXANT TESTS
Vehicle V V – – 0 263.4 ± 9.12
Almorexant 300 V 9.67 ± 0.95 – −7.2 244.3 ± 11.4
V 1.0 – 109.2 ± 6.7 −22.3 204.7 ± 10.6*
300 1.0 7.77 ± 0.75 105.6 ± 7.12 −2.5 204.2 ± 11.1*
DORA-12 TESTS
Vehicle V V – – 0 267.2 ± 12.9
DORA-12 100 V 3.03 ± 0.37 – −1.5 263.1 ± 13.5
V 1.0 – 130.6 ± 2.8 −29.1 189.4 ± 10.5*
100 1.0 1.25 ± 0.36 123.5 ± 5.0 −25.1 200.1 ± 9.1*
ANOVA, analysis of variance; SEM, standard error of the mean; V, vehicle.
aMean ± SEM.
*p < 0.05, significance versus vehicle-vehicle; #p < 0.05, significance versus vehicle-ethanol. Two-Way ANOVA was followed by post-hoc tests (Newman-Keuls
multiple comparison test).
non-benzodiazepines, zolpidem and eszopiclone—all impaired
rotarod performance and potentiated the effects of ethanol in
the current study. While all three compounds interact with the
same allosteric benzodiazepine binding site on GABA-A receptors
to increase their activity, the subunit specificity and pharma-
cokinetic properties of each differ, particularly that of diazepam
which has an extended plasma half-life relative to zolpidem and
eszopiclone (Graham et al., 1996; Rudolph et al., 1999; McKernan
et al., 2000; Bianchi, 2010; Gotter et al., 2013). This impair-
ment is observed across benzodiazepine and non-benzodiazepine
compounds and is likely a result of the widespread expression
of GABA-A receptors throughout the CNS (Sieghart and Sperk,
2002). Taken together, the results reveal that the distinct effects on
locomotor performance mediated by orexin receptor antagonists
vs. GABA-A receptor modulators are due to pathway-dependent
effects.
The differences between orexin antagonism and GABA-
receptor activation on locomotor performance were also high-
lighted in the context of sleep-promoting efficacy. DORA-12,
which promoted sleep at 30mg/kg to a similar or greater
extent relative to high doses of eszopiclone, zolpidem and
ethanol, exhibited no locomotor impairment. Even at 100mg/kg,
DORA-12 induced no locomotor impairment or ethanol interac-
tion. Almorexant administered at 300mg/kg, a dose well-above
that required for sleep-promoting effects (Brisbare-Roch et al.,
2007; Gotter et al., 2013), also left locomotor performance unaf-
fected. Comparative clinical studies will be needed to confirm
the translatability of these differences observed in the rat rotarod
assay.
In addition to comparing the magnitude of sleep promotion,
as measured by active wake reduction, the current work also
demonstrates clear differences in the sleep architecture induced
by GABA-A receptor modulators, DORA-12 and ethanol. At the
doses tested, both classes of drugs as well as ethanol signifi-
cantly promoted delta sleep to similar levels in the 2 h following
treatment. In the case of zolpidem, this was despite insignif-
icant effects on active wake reduction. This difference relative
to prior studies (e.g., Renger et al., 2004) was likely due to
the 2-h quantification performed here. The most striking differ-
ence between these classes of compounds was their effects upon
REM sleep. The highly significant increase in REM induced by
DORA-12 was diametrically opposed to the REM-suppressing
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effects of eszopiclone and zolpidem. These effects were consistent
with prior studies separately evaluating other DORAs (Brisbare-
Roch et al., 2007; Bettica et al., 2012a; Winrow et al., 2012)
and GABA-A modulators (Brunner et al., 1991; Renger et al.,
2004). Differential effects on REM sleep were also observed in
a recent study comparing several GABA-A modulators with the
orexin antagonist DORA-22; the GABA-A receptor modulators
eszopiclone and zolpidem were associated with dose-responsive
disruptions in EEG spectral profiles during sleep, while DORA-
22 produced only marginal changes in EEG measures during
compound-induced sleep (Fox et al., 2013). In the present study,
diazepam was highly effective in attenuating active wake; how-
ever, this GABA-A modulator did not attenuate REM. This may
be due to either GABA-A receptor subtype specificity differences
from other compounds in this class (Arbilla et al., 1985), or more
likely the limited 2-h analysis used here relative to this longer
half-life compound, since diazepam has been noted to attenuate
REM in prior studies (Renger et al., 2004). Ethanol attenuated
active wake and promoted delta sleep to a similar extent as
eszopiclone and DORA-12, but neither increased nor decreased
REM sleep.
GABA is the principal inhibitory neurotransmitter in the
nervous system, and as a consequence, GABA-A receptor mod-
ulators impact neurons throughout the CNS and modulate
numerous signaling events, many of which are not involved
with sleep promotion. Some of these additional CNS activ-
ities may be responsible for the unwanted effects associated
with GABA-A receptor agonists, including drowsiness at arousal
and induction of seemingly non-restorative sleep (Mohler,
2006). Consequently, some patients use alcohol in conjunc-
tion with GABA-A receptor modulators in an attempt to assist
with falling asleep. Indeed, aged Finnish males who use anx-
iolytics and sedatives (mainly benzodiazepines) are reportedly
more likely to be binge drinkers and heavy alcohol consumers
than those who do not take psychotropics (Ilomaki et al.,
2008).
Orexin neurons project to many regions in the brain including
discrete brain centers that are part of the sleep-arousal sys-
tem (Peyron et al., 1998; Marcus et al., 2001). Orexin receptor
antagonists may therefore become an important new class of ther-
apeutics that treat insomnia using a novel mechanism (Winrow
and Renger, 2013). Even though orexin receptor antagonists are
effective at promoting sleep at moderate doses, the observation
that they did not impair motor performance in rats (as measured
on the accelerating rotarod), or exacerbate the motor impair-
ment induced by alcohol, suggests that the potential for negative
motor side effects may be lower with orexin receptor antago-
nists than with GABA-A receptor modulators. The lowest dose
of GABA-A receptor modulators to attenuate motor activity sig-
nificantly on the rotarod was 3mg/kg for zolpidem, eszopiclone,
and diazepam, corresponding with ranges reported by other stud-
ies to promote sleep 1–3mg/kg for zolpidem, 3–10mg/kg for
eszopiclone and 1–3mg/kg for diazepam (Renger et al., 2004;
Fox et al., 2013; Gotter et al., 2013). Neither almorexant nor
DORA-12 affected latency to fall from the rotarod at doses rang-
ing from 30 to 300mg/kg and from 10 to 100mg/kg, respectively
DORA-12.30mg/kg induced similar or greater sleep-promoting
efficacy relative to highly impairing doses of eszopiclone and
zolpidem in the current work, and the sleep-promoting effects
were consistent with prior experiments (Fox et al., 2013). Given
that the animals treated with DORA-12 or almorexant were
able to perform without impairment, it appears that these
compounds induce sleep without affecting motor co-ordination
in rats.
The potential risks associated with combining GABA-A recep-
tor modulators (including benzodiazepines and benzodiazepine
receptor agonists) and alcohol are perhaps best underscored by
examining the links between their consumption and impaired
driving skills. It is well-established that alcohol alone disrupts
sleep, and can induce grogginess and decrease alertness (Stein
and Friedmann, 2005). Benzodiazepine use is associated with an
increased risk of on-the-road traffic accidents (Barbone et al.,
1998; Woratanarat et al., 2009; Chang et al., 2013), and indi-
viduals combining alcohol with long-acting benzodiazepines
are significantly more likely to be unsafe drivers than per-
sons driving under the influence of alcohol alone (Maxwell
et al., 2010). Furthermore, studies have demonstrated that drivers
involved in motor vehicle accidents often had detectable lev-
els of benzodiazepines alone and in combination with alcohol
(Christophersen and Morland, 2008; Ricci et al., 2008; Legrand
et al., 2013). Benzodiazepine use also increases the risk of falls
in the elderly (Leipzig et al., 1999; Ray et al., 2000; Ensrud
et al., 2002; Allain et al., 2005; Titler et al., 2011). When alco-
hol is combined with hypnotics, the frequency of falls and
hip fractures in the elderly increases further (Allain et al.,
2005). Interestingly, a recent study of next-day driving per-
formance, balance and cognitive tests in elderly (65–80 years)
healthy volunteers found no impairment by the orexin receptor
antagonist, suvorexant, whereas the GABA-A receptor modu-
lator, zopiclone, impaired these parameters (Vermeeren et al.,
2012).
In conclusion, these results demonstrate distinct differences
between the orexin antagonist and GABA-A receptor mecha-
nisms on sleep architecture and locomotor performance, and
their interaction with ethanol. When administered at sleep-
inducing doses, structurally distinct orexin receptor antago-
nists had no effect on rat rotarod performance and did not
potentiate the effect of ethanol, whereas benzodiazepine and
non-benzodiazepine GABA-A receptor modulators impaired
locomotor function and exacerbated the impairing effects of
ethanol on this task at doses well-below that required to induce
sleep. Furthermore, REM sleep differences were observed between
these classes of compounds where DORA-12 induced signifi-
cant increases in REM sleep as opposed to the REM-suppressing
effects of eszopiclone and zolpidem. Our results corroborate
the findings of Steiner and colleagues (Steiner et al., 2011)
who also reported an absence of motor disruption with the
orexin receptor antagonist almorexant and a lack of additive
effects when almorexant was co-administered with ethanol, and
align with data in human subjects demonstrating that almorex-
ant does not potentiate ethanol-induced motor or cognitive
deficits (Hoch et al., 2013). Clinical evaluation of the effects of
suvorexant and alcohol in combination in humans is currently
underway.
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